A radioimmunometric assay for the detection and characterization of lung cancer-associated antibodies in sera of lung cancer patients.
A radioimmunometric assay was developed from P3 lung carcinoma target cells to detect anti-lung cancer antibodies. Of 100 sera from lung cancer patients tested, 80 (80%) were positive. However, only 6/30 (20%) sera from cancer patients with other cancers, 1/25 (4%) of sera from patients with nonmalignant lung disease, and 0/20 sera from healthy donors were positive. Quantitative absorptions showed that sera from lung cancer patients cross-reacted with other lung cancers, gastrointestinal cancers, and/or fetal lung tissues, but not with breast carcinomas, melanomas, sarcomas, fetal skin, or normal lung tissues. Two lung cancer antigens were defined: LCA-1, which shared antigenic determinants with GI tumors and fetal lung tissues, and LCA-2, which showed cross-reactivity only with GI tumors.
D000328:Adult; D000912:Antibodies, Neoplasm / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology*; D002460:Cell Line; D003429:Cross Reactions; D000939:Epitopes / Q000032:analysis; D005770:Gastrointestinal Neoplasms / Q000276:immunology; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D008168:Lung / Q000196:embryology / Q000276:immunology; D008175:Lung Neoplasms / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011869:Radioligand Assay
D000912:Antibodies, Neoplasm; D000939:Epitopes; D006680:HLA Antigens